ZA202400405B - Methods of treating neurological diseases - Google Patents

Methods of treating neurological diseases

Info

Publication number
ZA202400405B
ZA202400405B ZA2024/00405A ZA202400405A ZA202400405B ZA 202400405 B ZA202400405 B ZA 202400405B ZA 2024/00405 A ZA2024/00405 A ZA 2024/00405A ZA 202400405 A ZA202400405 A ZA 202400405A ZA 202400405 B ZA202400405 B ZA 202400405B
Authority
ZA
South Africa
Prior art keywords
methods
neurological diseases
treating neurological
treating
diseases
Prior art date
Application number
ZA2024/00405A
Other languages
English (en)
Inventor
Leung Shui-On
Chong Chiho
Chuang Chingyi
Original Assignee
Sinomab Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinomab Bioscience Ltd filed Critical Sinomab Bioscience Ltd
Publication of ZA202400405B publication Critical patent/ZA202400405B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ZA2024/00405A 2021-07-13 2024-01-11 Methods of treating neurological diseases ZA202400405B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163221261P 2021-07-13 2021-07-13
PCT/CN2022/105077 WO2023284710A1 (en) 2021-07-13 2022-07-12 Methods of treating neurological diseases

Publications (1)

Publication Number Publication Date
ZA202400405B true ZA202400405B (en) 2025-03-26

Family

ID=84919904

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2024/00405A ZA202400405B (en) 2021-07-13 2024-01-11 Methods of treating neurological diseases

Country Status (10)

Country Link
US (1) US20240309089A1 (cg-RX-API-DMAC7.html)
EP (1) EP4370153A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024527401A (cg-RX-API-DMAC7.html)
KR (1) KR20240042443A (cg-RX-API-DMAC7.html)
CN (1) CN117999096A (cg-RX-API-DMAC7.html)
AU (1) AU2022310081A1 (cg-RX-API-DMAC7.html)
CA (1) CA3225077A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024000591A (cg-RX-API-DMAC7.html)
WO (1) WO2023284710A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202400405B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019099707A1 (en) * 2017-11-16 2019-05-23 Kite Pharma, Inc Modified chimeric antigen receptors and methods of use
WO2024197258A1 (en) * 2023-03-23 2024-09-26 Klaritos, Inc Methods of treating alzheimer's disease
WO2025190311A1 (en) * 2024-03-12 2025-09-18 Sinomab Bioscience Limited Method of identifying anti-siglec antibodies possessing cis-trans converter properties, anti-siglec antibodies and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201203442D0 (en) * 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
US9066928B1 (en) * 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9908933B2 (en) * 2013-08-05 2018-03-06 St. Vincent's Institute Of Medical Research Antibody therapy for amyloid beta disease
WO2017196432A1 (en) * 2016-05-12 2017-11-16 La Jolla Institute For Allergy And Immunology Compositions and methods for diagnosing and treating neurodegenerative disease
US20210380685A1 (en) * 2018-10-18 2021-12-09 Sinomab Bioscience Limited Methods of Treating Rheumatoid Arthritis
ES2821599A1 (es) * 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer

Also Published As

Publication number Publication date
US20240309089A1 (en) 2024-09-19
EP4370153A1 (en) 2024-05-22
JP2024527401A (ja) 2024-07-24
MX2024000591A (es) 2024-03-19
CA3225077A1 (en) 2023-01-19
WO2023284710A1 (en) 2023-01-19
EP4370153A4 (en) 2025-05-07
AU2022310081A1 (en) 2024-02-01
KR20240042443A (ko) 2024-04-02
CN117999096A (zh) 2024-05-07

Similar Documents

Publication Publication Date Title
IL288574A (en) Oligonucleotides and methods for use in the treatment of neurological diseases
GB202020573D0 (en) Novel methods of therapy
ES3066136T3 (en) Methods of treating fabry disease
EP4213891A4 (en) METHODS OF TREATING NEUROLOGICAL DISEASE
EP4267196A4 (en) TREATMENT OF NEUROLOGICAL DISEASES
IL315503A (en) Treatment methods
GB202020572D0 (en) Novel methods of therapy
IL320711A (en) Treatment methods
EP4370153A4 (en) Methods of treating neurological diseases
IL290892A (en) Methods of treating vascular diseases
IL321201A (en) Methods for treating neurological disorders
IL290250A (en) Targeted gene therapy to treat neurological diseases
GB202201824D0 (en) Methods of treatment
IL326065A (en) Methods of treating medical conditions and diseases
GB202313514D0 (en) Treatment of inflammatory diseases
GB202201825D0 (en) Methods of treatment
GB202201819D0 (en) Methods of treatment
HK40109636A (en) Methods of treating neurological diseases
IL290351A (en) Compositions and methods for the treatment of neurological diseases
IL312155A (en) A method for treating cancer
IL325768A (en) Methods for treating neurological diseases
HK40117579A (en) Methods of treating neurological disorders
IL327063A (en) Methods for treating MAT2A-related diseases
GB202306675D0 (en) Methods of treatment of inflammatory diseases
GB202304900D0 (en) Methods of treatment of inflammatory diseases